Competitive landscape

Proven rule. Every body claim traces to a source. Inferred or single-sourced-shaky claims live in section 4.

Kicker. MEDvidi is not competing in "online mental health". It is competing in a much narrower place: the set of businesses willing to put a Schedule II prescription behind a same-week video visit that a patient pays for out of pocket. That set is small, it is priced far below MEDvidi, and it is shrinking for reasons that have nothing to do with MEDvidi's product. Two independently-audited public filings from the last six weeks say the category's cash-pay wallet is actively draining into insurance: BetterHelp's revenue fell 12% year over year to $212.6M in Q2 2026 with cash-paying users declining faster than insurance could replace them, and Talkspace's consumer (cash) line fell 25.4% to $3.3M while its insurance line grew 27.1% to $51.5M. Meanwhile the venture money in US telemental health went almost entirely to in-network models — Talkiatry $210M in February 2026 (>$400M total, 800+ employed psychiatrists, 170M covered lives), Grow Therapy $150M in March 2026 at a $3B valuation, Rula and Headway at $2.3B each — while the closest cash-pay analogue to MEDvidi, Klarity Health, has raised about $10M in total. And the peer that ran MEDvidi's old business model — a monthly membership with automatic refills — is Done, whose founder was sentenced on 7 July 2026 to six years in federal prison. MEDvidi's own Wayback history shows it ran that same membership model in 2022 and abandoned it for flat per-visit pricing by early 2023. That is the single most important thing in this Area: MEDvidi's price is not a positioning choice, it is a compliance-shaped business model, and its $195/$159 per-visit structure is the artifact of surviving the thing that killed its closest competitors.

Source legend

1. What we found

1.1 The axis that actually decides outcomes: who pays, crossed with what gets prescribed

Segmenting this market by marketing category ("online therapy", "telepsychiatry", "ADHD app") produces a useless map. Two variables decide who competes with whom, what the price can be, and who survives a regulatory change:

1. Who pays — the patient's own card, or a payer (commercial plan, Medicare, Medicaid, employer).
2. What is prescribed — nothing, non-controlled psychiatric medication only, or controlled substances up to Schedule II.

MEDvidi sits in one cell: patient's card × Schedule II. Its own site states cash-pay with no insurance, prices of $195 for a 30-minute initial visit and $159 for a 15-minute follow-up, coverage in 35 states, and providers "certified to … prescribe medications online, including controlled substances", spanning Schedule II–V [WEB]. Its clinician job posting requires "clinical experience with prescribing controlled substances", a valid DEA registration, and two years of controlled-substance prescribing [WEB]. There is no therapy product at all: zero URLs matching therap* in its page sitemap, and zero mentions of therapy or therapists in the homepage text [SM] [WEB]. MEDvidi is a prescribing-only, cash-only, controlled-substance-inclusive business. Everything below follows from that.

The six segments, and who is actually in each as of August 2026:

(1) Cash-pay online psychiatric prescribing, controlled substances included. MEDvidi's true competitive set. Klarity Health (marketplace, self-pay from $49–51, "1,000+ licensed mental health providers in 50 states", appointments within 24 hours, explicitly lists Adderall, Vyvanse and Ritalin as options) [COMP-KLARITY]; Done ($199 or $299 first month then $79/month membership, no insurance accepted for appointments) [COMP-DONE]; ADHD Online / Mentavi Health ($199 assessment, $199 initial appointment, $175 follow-ups, explicitly "we do not accept or directly bill insurance" but issues superbills, treatment available in 40 states) [COMP-ADHDONLINE]; Circle Medical, which straddles this cell and the next ($120 cash per visit, or $0–35 with accepted PPO insurance) [COMP-CIRCLE]; and Sesame Care as the marketplace price floor (a "$79/month" Mental Health Rx subscription with same-day video visits and refills, no insurance) [COMP-SESAME].

(2) Insurance-based online psychiatry. Talkiatry (insurance-only positioning; "Most Talkiatry patients pay around $30 out of pocket per visit") [COMP-TALKIATRY]; Brightside Health (insurance including Medicare and Medicaid, self-pay psychiatry $95/month, all 50 states plus DC) [COMP-BRIGHTSIDE]; Rula (in-network with 100+ plans, "$15 average cost per session with insurance", all 50 states, cash psychiatry $225 intake / $175 follow-up) [COMP-RULA]; Grow Therapy and Headway as the credentialing-and-billing rails underneath thousands of independent prescribers [COMP-GROW] [MKT]; and Cerebral in its successor state — still operating, but having stopped prescribing controlled substances entirely [REV].

(3) Therapy-first platforms with prescribing bolted on. BetterHelp (therapy, plus psychiatry through the Uplift acquisition) and Talkspace. Both matter here not as competitors for MEDvidi's click but as the category's most reliable instrumentation — see 1.6.

(4) Full-stack DTC pharmacy brands that added mental health. Hims & Hers ("Prescription- strength psychiatry medications from $49/mo", no insurance) and Ro, LifeMD. The decisive fact: Hims states in its own safety copy that "Controlled substances, including amphetamines (such as Adderall) or benzodiazepines (such as Xanax and Valium) are not available through our platform" [COMP-HIMS]. The largest, best-capitalised DTC prescriber in America has deliberately fenced itself out of MEDvidi's cell.

(5) The GLP-1 weight cohort. Hims ($39 first month then $149/month membership plus medication at $149–$299/month) [COMP-HIMS]; LifeMD ($39 first month then $149/month program fee, Wegovy pen from $199 cash or "$0–$25 co-pay" with insurance via a NovoCare route, and ~108,000 weight-management subscribers) [COMP-LIFEMD] [SEC]; Found, which now leads with "Covered by top insurance plans", "Most members pay less than $30/visit" and a Medicare GLP-1 bridge at $50/month [COMP-FOUND]. MEDvidi entered this vertical with per-visit cash pricing and no pharmacy — see 1.9.

(6) ESA-letter operators. ESA Doctors lists $159 for an ESA letter and $199 for a psychiatric-service-dog letter [COMP-ESAD]. MEDvidi sells an ESA letter as a service line [WEB]. This is the one segment where insurance is structurally irrelevant, which is exactly why it is both attractive and hazardous — see 1.10.

One disqualification, to save the reader a wrong assumption: Frida (talkwithfrida.com) is Canadian. Its pricing is a one-time CAD $599 diagnostic assessment then CAD $99 per appointment, and it discusses "private insurance plans that offer a health spending account" in Canadian terms [COMP-FRIDA]. It is not in MEDvidi's market and should not appear in a US competitive slide.

1.2 The comparison table, every price sourced and dated

All figures are the operator's own published price as read on the date shown. Where a company publishes more than one number for the same thing, the conflict is recorded in section 3 rather than averaged away.

1.3 Where MEDvidi actually sits on price: above market per minute, at market per year

Two arithmetic views, because the headline number flatters MEDvidi and the per-minute number condemns it.

Price per clinical minute (operator's own published duration)
  MEDvidi initial     $195 / 30 min  = $6.50 /min
  MEDvidi follow-up   $159 / 15 min  = $10.60 /min
  Rula   initial      $225 / 60 min  = $3.75 /min   (cash rate, insurance also available)
  Rula   follow-up    $175 / 30 min  = $5.83 /min
  Talkspace initial   $299 / 60 min  = $4.98 /min
  Circle Medical      $120 / visit   (duration not published)

[REASON] on [WEB] [COMP-RULA] [COMP-TALKSPACE] [COMP-CIRCLE]

MEDvidi's follow-up is the most expensive minute of psychiatric time in this set — 1.8× Rula's cash follow-up minute and 2.8× Rula's cash intake minute. A candidate should not say "MEDvidi is premium priced" without saying where: the initial visit is roughly at market for cash-pay ADHD care ($195 vs ADHD Online's $199, Klarity's comparison-table claim of $189 for ADHD Online, Done's $199 first month). It is the 15-minute $159 follow-up that is the outlier, and it is also where the recurring revenue lives.

Annual out-of-pocket cost of staying treated (arithmetic, not a quote)
  MEDvidi, quarterly follow-ups   $195 + 4 x $159 =   $831 / yr
  MEDvidi, monthly follow-ups     $195 + 11 x $159 = $1,944 / yr
  ADHD Online                     $199 + 4 x $175 =   $899 / yr
      (checks out: adhdonline.com itself publishes "$899 (1 year)")
  Rula, cash psychiatry           $225 + 4 x $175 =   $925 / yr
  Done                            $199 + 11 x $79  = $1,068 / yr
  Brightside self-pay             12 x $95         = $1,140 / yr
  Circle Medical, cash            5 x $120         =   $600 / yr
  Circle Medical, insured         5 x $35          =   $175 / yr
  Talkiatry, insured              5 x $30          =   $150 / yr
Assumptions: 5 encounters a year is the insured-psychiatry pattern implied by
Brightside's and Talkiatry's own copy; the MEDvidi monthly case is the worst case
implied by controlled-substance refill cadence, not an observed average.

[REASON] on [WEB] [COMP-ADHDONLINE] [COMP-RULA] [COMP-DONE] [COMP-BRIGHTSIDE] [COMP-CIRCLE] [COMP-TALKIATRY]

The verdict on position: at market against cash-pay peers, 5–13× the out-of-pocket cost of insured psychiatry.

  $831 / $150 =  5.5x     (MEDvidi quarterly vs Talkiatry insured)
$1,944 / $150 = 13.0x     (MEDvidi monthly  vs Talkiatry insured)

[REASON]

That ratio tells you exactly who converts at MEDvidi's price, and it is not "people who cannot find a psychiatrist". It is people for whom one of four things is true: they are uninsured or pre-deductible so cash is genuinely cheaper than a claim; they need an appointment this week rather than in three months; they want a Schedule II prescription that in-network psychiatry either refuses or slow-walks; or they want something insurance will never buy — an ESA letter, an off-label request, a weight-loss prescription. Every one of those four is a speed-or-permission purchase, not a price purchase. MEDvidi's price is therefore defensible only for as long as the permission is scarce.

1.4 MEDvidi's own history says the model is compliance-shaped, not marketing-shaped

This is the finding that reframes everything else, and it comes from MEDvidi's own archived pages.

Mid-2022 — a membership business. The 2022-06-01 capture of the homepage sells a subscription: "Prescription management $49 for your first month and as low as $99 starting the second one!", a Medication management plan whose bullet list reads "Schedule 2-5 drugs prescriptions / Billed monthly / Cancel anytime", a Therapy plan at $199 first month with bi-weekly therapist sessions, and a Therapy + Medication management plan at $219 first month. There is a "SmartCare symptom checker" front door [ARC].

January and June 2023 — a discounted, variable per-visit business. "Book an initial appointment at a cost from $25 to $195, depending on the chosen service and your location"; follow-ups "from $99 to $175 per visit"; a promotional "from $25 for your initial visit and as low as $99 per visit afterward" [ARC].

December 2023 to today — flat premium per-visit. $195 and $159 appear on the homepage in the 2023-12-08 capture and in every capture checked since: 2024-01-04, 2025-01-05, 2026-01-03, 2026-06-24, and the live page on 2026-08-18 [ARC] [WEB].

Read that sequence next to what happened to the peers who kept the membership: Done's $79/month auto-refill subscription is the mechanism the government prosecuted, and its founder and clinical president were sentenced on 2026-07-07 to six years and two years respectively [PRESS-DONE] [COMP-DONE]. Cerebral abandoned controlled substances entirely [REV]. Ahead shut down in 2022 [REV].

Two conclusions a VP of Product should carry into the room. First, MEDvidi's pricing architecture is a control: every prescription is attached to a billed clinical encounter, so there is no revenue line that pays for medication without a visit. That is worth more than it costs. Second, the price has not moved in over two and a half years while the peer set re-platformed onto insurance — so the pricing power is either real and untested, or it is untested and stale. Nobody has run the experiment.

Alongside the frozen price, the footprint tripled. The 2024-01-04 capture lists providers licensed in 13 states: AZ, CA, CO, FL, IL, IN, NY, NC, OH, PA, TX, VA, WI [ARC]. The site today lists 35 [WEB].

13 states (2024-01-04)  ->  35 states (2026-08-18)
  +22 states over ~31 months = 2.7x, ~0.71 new states/month

[REASON] on [ARC] [WEB]

State expansion, not price, has been the growth engine. That is a supply-and-licensing achievement rather than a product one, and it is nearly exhausted: 35 of 51 jurisdictions are done, and the remaining ones are mostly small.

1.5 Scale, honestly: everyone who matters is one or two orders of magnitude larger

The public filings are the only unarguable numbers in this Area. All four are for the quarter ended 2026-06-30 [SEC].

Private-company scale, weaker sourcing, order of magnitude only: Talkiatry raised $210M in February 2026 for a total above $400M, employs "more than 800 full-time psychiatrists", has delivered 3 million patient visits and is in-network with 100+ insurers covering 170M+ lives [PRESS-TALKIATRY]. Grow Therapy: $150M Series D on 2026-03-03, $328M total, $3B valuation. Headway: $321M total, $2.3B valuation. Rula: ~$263M total, ~$2.3B valuation. Brightside: roughly $106–114M total depending on the aggregator, latest round July 2025. Circle Medical: majority-acquired by WELL Health Technologies in 2020 for about $14M, i.e. it sits inside a listed parent. Klarity Health: about $10M total raised, 74 employees as of 2026-01-31, with a 2023 revenue figure of $7.3M from a self-reported database. Done: 281 employees as of 2026-03-31 [MKT].

Consumer-scale proxy from the App Store, US storefront, 2026-08-18 [APPS]: Hims 93,270 ratings; Talkspace 46,497; Circle Medical 29,949; Cerebral 32,249; LifeMD 15,742; Brightside Health 10,399; Sesame 9,571; Grow Therapy 8,076; Talkiatry only 30 ratings on an app first released 2026-04-29. No app under the MEDvidi name exists — consistent with the Orchestrator's App Store search. Klarity, Done and ADHD Online likewise returned no first-party app in this search.

MEDvidi's own scale is not published anywhere this Area could reach. The only anchor is the org described in the posting — 2 Directors of Product, 8 PMs, 3 Designers, 1 Director of Data & Analytics, 6 analysts, 1 data engineer, 1 Lead PMM, 1 VP Engineering, 30+ Engineers & QAs [JD] — which is about 54 product-and-engineering people before counting clinicians, support, marketing or finance.

Order-of-magnitude revenue floor implied by the product+eng org  [ESTIMATE]
  Headcount in scope (from the posting)                     ~54 people
  Fully-loaded cost per head, low-cost-geography assumption  $45k - $80k
  Annual product+eng cost                                    $2.4M - $4.3M
  Product+eng as share of revenue in DTC health              10% - 15%
      (LifeMD spends 59.3% of revenue on sales & marketing alone [SEC],
       which leaves little room for engineering to be a large share)
  Implied revenue                    $2.4M/0.15 = $16M  ...  $4.3M/0.10 = $43M

[REASON] on [JD] [SEC]

So MEDvidi is plausibly a $15M–$45M revenue business — bigger than Klarity, one-fifth to one-fiftieth of the public comparables, and funded by cash flow rather than by a $210M round. That number is an estimate built on two assumptions and belongs to A3 to confirm or kill; it is stated here only because "where does MEDvidi stand" is unanswerable without an order of magnitude. If it is right, the strategic fact of this Area is that MEDvidi is a profitable minnow in a pond of subsidised whales — which cuts both ways. It cannot outspend anyone on acquisition, and it does not need to; it also cannot survive a year of negative unit economics that Talkiatry could shrug off.

1.6 The structural question, answered: cash-pay is transitional for therapy and general psychiatry, and narrowly durable only where the payer cannot go

This is where the Area stops describing and takes a position, and the evidence is unusually good because two of the businesses involved are SEC registrants who had to write down what happened.

BetterHelp, the largest cash-pay behavioural telehealth business in America, is converting to insurance and it is hurting. From Teladoc's 10-Q for the quarter ended 2026-06-30, filed 2026-07-30 [SEC]:

• "BetterHelp total revenue decreased by $27.8 million, or 12%, to $212.6 million for the three months ended June 30, 2026 … reflecting a faster than expected shift in demand from Consumer and Other to Insurance Covered Services for which we have not yet been able to fully increase our capacity to serve."
• "During May 2026, the rate of decline in revenue from cash-paying users accelerated beyond the assumptions reflected in our previously expected results, and information available in late May and June indicated that the trend was more persistent and significant than previously anticipated."
• The bottleneck was not demand, it was licensed supply and payer plumbing: conversion "was constrained by the availability and capacity of providers who were appropriately licensed in the applicable state, credentialed and enrolled with the applicable payer, available to provide services and accepting new patients, as well as by insurance-specific eligibility, matching, booking and scheduling workflows."
• Paying users fell 11% to 0.346 million; advertising and marketing was cut 17% to $111.7M "to better align related demand generation with available network capacity"; segment adjusted EBITDA for the half fell 88% to $2.4M; and the BetterHelp goodwill balance of $283.2M required an impairment test after management revised expected performance.
• The company's own risk-factor heading: "Our BetterHelp segment has experienced, and may continue to experience, declines in revenue from users who pay directly out-of-pocket, and growth in insurance-covered services may not offset those declines as quickly as we expect or at all."

BetterHelp implied revenue per paying user per month, Q2 2026
  $212.6M / 3 months / 0.346M users = $205 per user per month

[REASON] on [SEC] — i.e. the cash-pay consumer wallet in behavioural telehealth was worth roughly $205/month at its largest scale, and that wallet is the one shrinking.

Talkspace shows the same migration from the other side. Q2 2026: total revenue $61.7M (+13.6%), payor revenue $51.5M (+27.1%), consumer revenue $3.3M (−25.4%) [SEC].

Talkspace revenue mix, Q2 2026
  Payor      $51.5M / $61.7M = 83.5%
  Consumer    $3.3M / $61.7M =  5.3%

[REASON] on [SEC]

Cash-pay is now a rounding error at the company that pioneered DTC therapy subscriptions.

Found shows it in weight care. Its home page now leads with "Start with a free insurance check", "Covered by top insurance plans", "Most members pay less than $30/visit", and a Medicare GLP-1 bridge program [COMP-FOUND].

And the money followed. Every large 2024–2026 round in this Area went to an in-network model: Talkiatry $210M (Feb 2026), Grow Therapy $150M at $3B (Mar 2026), Headway at $2.3B, Rula at $2.3B [PRESS-TALKIATRY] [MKT]. The cash-pay analogues raised $10M (Klarity), were prosecuted (Done), retreated (Cerebral) or died (Ahead) [MKT] [PRESS-DONE] [REV].

So: is cash-pay, no-insurance, per-visit durable in 2026? The honest answer has two parts.

For therapy and routine psychiatry it is transitional and the transition is already happening — proven by two sets of audited numbers above, not by opinion.

For what the payer cannot or will not buy it remains durable, and it is a small, defensible strip: same-week access, willingness to prescribe Schedule II after a video visit, ESA letters, and cash GLP-1 access. MEDvidi lives entirely on that strip. The strip's width is set by regulation, not by product quality — which is why the company's own FAQ statement that DEA telemedicine flexibilities run through 2026-12-31 is the load-bearing sentence on the whole site [WEB], and why A4's answer determines whether this Area's verdict is "narrow moat" or "cliff".

One more thing MEDvidi has already told the market, and it settles the debate about intent: on its weight-loss service page, under "Does MEDvidi accept insurance?", the answer is "Currently, MEDvidi doesn't accept insurance. We work on collaborating with insurance providers and we'll notify our patients once this option becomes available." [WEB] The company is not defending cash-pay as an ideology. It is publicly signalling a move onto payer rails — and BetterHelp's Q2 filing is a precise, dated map of how that move goes wrong when licensed-and-credentialed supply is the constraint.

1.7 What enforcement did to the direct set, and what it left MEDvidi

The regulatory detail belongs to A4; the competitive consequence belongs here.

Done Global's founder Ruthia He was sentenced on 2026-07-07 to six years in federal prison with a $1M fine, and its clinical president to two years, in a case DOJ and DEA describe in terms of a $90–100M scheme distributing over 37 million Adderall pills and defrauding insurers of more than $12M [PRESS-DONE]. Six weeks later, on 2026-08-18, donefirst.com is still live and still selling the same structure this Area fetched: "$199 for the first month, then $79/month" in one block and "$299 for the first month, then $79/month" in another, with the feature bullets "Easy automatic refill" and "Worry-free ongoing care" [COMP-DONE]. The page also still hosts the 2024 "Statement from Done Global" ("Done Global will continue to operate") and, tellingly, un-replaced website-template placeholder pricing for a product called "Tiles" at $8 per user per month [COMP-DONE]. That is what a competitor looks like when nobody is maintaining the storefront.

The competitive read-through:

1. MEDvidi is beating Done, and it is beating it on a structural difference rather than execution — Done still sells prescription continuity as a subscription; MEDvidi sells clinical encounters. In a category where the largest enforcement action in its history targeted exactly that difference, that is the single most valuable asset MEDvidi has, and it is invisible on the marketing site.
2. Demand does not disappear when a competitor is disgraced; it moves. Patients who lose access to Done or Cerebral's stimulant service look for someone who will still prescribe. MEDvidi is one of a handful of destinations. Inbound demand quality gets worse at the same time as volume gets better, which is a triage problem — and triage is a product problem.
3. Scrutiny is a shared externality. The DOJ theory reportedly extends to platform design, clinical protocols and incentive structures, i.e. to things a product organisation ships. A VP of Product here owns compliance surface, not just funnel surface.

1.8 The category's real bottleneck is the pharmacy, and nobody in the set has solved it

MEDvidi publishes a whole FAQ page on pharmacy failure [WEB]. Read as a competitive document, it is a list of the ways the product fails after the money is taken: "Some pharmacies, large chains and small independents may not accept electronic prescriptions (eRx) from telehealth services due to their specific policies"; pharmacies refusing "due to issues with the doctor's license"; "MEDvidi's providers cannot increase supply, order, or transfer controlled substances such as Ritalin, Adderall, etc. due to nationwide restrictions and remands"; providers "do not send electronic scripts for controlled substances to multiple pharmacies for stock availability"; refills processed same day by the Care Team but "up to 72 hours" for provider approval; "refills can be requested only 25 days after the previous prescription's fill date".

This is not MEDvidi-specific. Third-party reporting on Circle Medical says CVS will not fill controlled-substance prescriptions written by its providers [REV]. The Klarity ADHD page carries the disclaimer that "Not all providers on Klarity Health prescribe all medications, particularly medications that are controlled substances" [COMP-KLARITY].

The asymmetry is important. The full-stack DTC brands own fulfilment — Brightside mails medication at "$15 per fill" [COMP-BRIGHTSIDE], Hims and LifeMD ship from their own supply chain [COMP-HIMS] [COMP-LIFEMD] — but none of them will touch Schedule II. MEDvidi is in the one cell where the prescription is the product and the fulfilment is somebody else's retail counter. Nobody in the competitive set has built the missing layer: real-time "which pharmacy near you both stocks this and accepts telehealth eRx" routing. That is an unclaimed product moat sitting in plain sight, and it is the thing patients actually churn on.

1.9 In the GLP-1 vertical MEDvidi is structurally out of position

The weight-loss category has standardised on one shape, and it is not MEDvidi's. Hims: "$39 in your first month, then $149/mo" membership, with medication priced separately at $149–$299/month [COMP-HIMS]. LifeMD: "$39 for your first month, and just $149 a month thereafter", program fee explicitly excluding medication, plus Wegovy at "$199 (pen)" cash or "$0–$25 co-pay" through an insurance-verification route [COMP-LIFEMD]. Found: insurance verification first, "less than $30/visit", Medicare bridge at $50/month [COMP-FOUND].

MEDvidi sells the same clinical service at $195 initial and $159 per follow-up, with one bundle at $249 for "an initial assessment and a follow-up appointment" marketed as "Save $105", and no medication supply at all — its own page says prescriptions "may be delivered directly to pharmacies" [WEB].

Twelve-month cost of a GLP-1 relationship, clinician fees only  [ESTIMATE]
  MEDvidi:  $249 bundle + 4 more follow-ups x $159        = $885
  MEDvidi:  $249 bundle + 10 more follow-ups x $159       = $1,839
  Hims:     $39 + 11 x $149                               = $1,678  (includes app, care team)
  LifeMD:   $39 + 11 x $149                               = $1,678  (includes coaching, labs)
Assumption: GLP-1 titration realistically needs monthly-to-quarterly contact.
Medication cost excluded from all rows; Hims and LifeMD also monetise the medication,
MEDvidi does not.

[REASON] on [WEB] [COMP-HIMS] [COMP-LIFEMD]

The fee levels are comparable, but the competitors' fee buys a bundle that includes drug sourcing, coaching, labs and an app, and their $39 entry point beats a $195 wall at the top of the funnel. More importantly, MEDvidi has no share of the medication economics, which is where Hims' revenue growth came from — cost of revenue up 112% year over year on "increased product and packaging costs of 141%" [SEC]. MEDvidi is renting out clinical minutes into a market whose winners are pharmacies with a doctor attached. The one interesting detail is that the $249 bundle exists at all: it is the only packaged price anywhere in MEDvidi's architecture, and it appears in the newest vertical.

1.10 ESA letters: the only genuinely payer-proof line, and the one with the worst optics

ESA Doctors sells an ESA letter for $159 and a psychiatric-service-dog letter for $199, claims "a decade of experience" and "having helped 100,000 people", and offers "Full refund if your letter doesn't work" [COMP-ESAD]. MEDvidi lists ESA letters as a service [WEB].

Insurance will never pay for this, so it is immune to the migration described in 1.6. It is also a documentation product sold to a consumer with a housing or travel motive, adjacent in kind to the "letter mill" pattern that regulators and prosecutors find easy to describe. A clinical-encounter-priced business that also sells letters has to decide which of the two it is when a regulator reads the site. This is a deliberate decision for the CEO, not a backlog item.

1.11 The same nurse practitioners are being recruited by everyone, and MEDvidi's pitch is operational relief

Supply is the constraint that BetterHelp's filing named explicitly [SEC], and it is contested. Compare the two recruiting propositions:

Grow Therapy to prescribers: join as an independent 1099 contractor with clinical autonomy; "credentialing, insurance enrollment, and billing handled"; 125+ insurance partners; "paid per session on a weekly basis"; "your pay is protected from insurance payor clawbacks"; profile promoted in the directory and on Zocdoc [COMP-GROW]. Rula, Headway and Talkiatry compete on the same ground, Talkiatry by employing psychiatrists outright — 800+ of them [COMP-RULA] [PRESS-TALKIATRY].

MEDvidi to prescribers, on its Florida provider vacancy: contractor engagement; "No need to hire or manage an Administrative Assistant — our system provides them for free"; "Automated admin tasks — forget about manually downloading PDMP reports"; "We offer a free prescribing license, so we cover the cost"; "our platform is completely free, saving you thousands in software costs" unlike "alternatives like advanced MD"; and "The lowest no-show rate in the market — ensuring more consistent patient engagement and income for you". Requirements: a physician with 5+ years, valid DEA, valid medical licence, and two years of controlled- substance prescribing [WEB].

That is a coherent and unusual pitch: MEDvidi is not competing for clinicians on rate or on insurance access, it is competing on removing administrative labour and guaranteeing filled slots. It is also the reason the three shipped AI features matter strategically rather than cosmetically. AI Scribe, Chart Review AI and the Agentic AI Receptionist [JD] all reduce clinician and support minutes per encounter — which is precisely the currency of MEDvidi's recruiting promise and precisely what the marketplaces cannot copy without owning the workflow. In this Area's terms, the AI programme is a supply-side moat presented as a patient-side feature.

1.12 The verdict: which competitor to fear, and which one MEDvidi is beating

Fear Circle Medical. It takes the identical click — someone searching for online ADHD treatment and a stimulant prescription — and it prices the same encounter at $120 cash or $0–35 with insurance, in 32 states, with controlled-substance prescribing permitted everywhere it operates except Georgia, Ohio, Michigan and North Carolina; it has a 29,949-rating iOS app at 4.82 stars; and it sits inside a listed parent, WELL Health Technologies, so it is not dependent on the next venture round [COMP-CIRCLE] [APPS] [REV] [MKT]. Against MEDvidi's 35 states, no app, and $195/$159 cash, Circle wins on price, wins on mobile, and matches on the one permission MEDvidi sells. If it finishes its state expansion, MEDvidi's premium has nothing left to stand on except speed.

Fear Hims & Hers as tail risk, not present risk. It has 2.9 million subscribers, $753.2M of quarterly revenue, its own fulfilment, and it explicitly does not prescribe amphetamines or benzodiazepines today [SEC] [COMP-HIMS]. The day a DEA special-registration regime makes telehealth Schedule II prescribing routine and auditable, that self-exclusion becomes a product decision rather than a legal one, and MEDvidi's entire market becomes a feature in somebody's $92-a-month subscription. Regulatory relief is not automatically good news for MEDvidi — the same rule that removes its cliff also removes its moat.

Fear Talkiatry structurally. $210M raised in February 2026, 800+ employed psychiatrists, in-network with 170M lives, an explicit AI platform narrative, and editorial pages built by medication name including Adderall and Vyvanse [PRESS-TALKIATRY] [COMP-TALKIATRY]. It is competing for the same medication-intent search term while charging the patient about $30. Its weakness is real and worth noting: an iOS app launched 2026-04-29 with 30 ratings and a 2.56 average [APPS] — a company that scaled clinicians faster than consumer product.

MEDvidi is beating Done, and beating Cerebral by default. Done's storefront is unmaintained and its founder is in prison for the mechanism it still advertises [COMP-DONE] [PRESS-DONE]; Cerebral has withdrawn from controlled substances entirely and now sells therapy and non-controlled medication [REV]. Both were better-funded than MEDvidi and both vacated the cell MEDvidi occupies. It is also, on price and completeness, beating Klarity on trust and losing to it on reach: Klarity claims 50 states and 1,000+ providers on $10M of capital, but with self-serving comparison content and inconsistent prices [COMP-KLARITY] [MKT].

2. Capability / object table

3. Reconciliation notes

Reconciliation note — Klarity's own self-pay price. helloklarity.com home says "Self-pay starts at $49"; its ADHD service page says "self-pay from $51" twice and then "Starting at $85" in its comparison table — all three fetched on 2026-08-18 [COMP-KLARITY]. Resolved in favour of quoting the range rather than a number: Klarity is a marketplace where the provider sets the price, so "from $49–51, with ADHD visits advertised from $85" is the only defensible statement. The lesson for MEDvidi is that Klarity's advertised floor is a bait number, and MEDvidi's $195 is a real one.

Reconciliation note — Circle Medical's price. Circle's own site says $120 cash per appointment [COMP-CIRCLE]; Klarity's comparison table says Circle costs $179 [COMP-KLARITY]. Resolved in favour of Circle's own page: an operator's price on its own site outranks a competitor's marketing table. Klarity's same table also assigns ADHD Online a "2.4/5" star rating and itself "4.5/5", which is self-serving on its face.

Reconciliation note — Done's two prices. Done's home page shows "$199 for the first month, then $79/month" in one block and "$299 for the first month, then $79/month" in another, in the same fetch on 2026-08-18 [COMP-DONE]. Not resolved; both are recorded. The most likely explanations are an un-cleaned A/B variant or a stale block, and the page also contains unreplaced website-template pricing, which supports the "unmaintained" read.

Reconciliation note — is Done still operating? A review site reached via search states "Done is no longer operating" [REV], while an aggregator reports 281 employees as of 2026-03-31 [MKT] and Done's own site served a live, priced, bookable storefront to this session on 2026-08-18 [COMP-DONE]. Resolved in favour of the live fetch: Done is trading. The review site is either wrong or was written about the 2024 indictment and never updated.

Reconciliation note — ADHD Online's follow-up price. The same pricing page shows "$185 for each follow-up" in a headline block and "$175" in the FAQ and in the annual-cost table [COMP-ADHDONLINE]. Resolved in favour of $175 for arithmetic, because $175 is the number that reconciles with the site's own published "$899 (1 year)" figure: 199 + 4 x 175 = 899 [REASON].

Reconciliation note — Cerebral's current pricing. Cerebral's live pages render only through JavaScript and returned no text to this session, and the Wayback captures of /plans are also empty. The prices quoted in secondary sources (medication management ~$180 billed quarterly, therapy $175/session) are [REV]-grade only and are therefore not used in the comparison table. What is well-supported is the direction: Cerebral no longer prescribes controlled substances.

Reconciliation note — MEDvidi versus "MEDVi". A separate GLP-1 telehealth company trading as MEDVi appears in the same search results and is confused with MEDvidi by review sites, which note that BBB complaints about the mental-health company MEDvidi Inc. of San Jose get mixed into MEDVi's reputation and vice versa [REV]. The two are different companies. Claims attached to MEDVi (an FDA warning letter, an F BBB rating, a partner data breach) are not claims about MEDvidi and are parked in section 4 unverified. This matters competitively because MEDvidi now sells weight loss under a nearly identical brand string.

4. Open Questions / Parked

1. MEDvidi's revenue and patient volume are unknown. The $15M–$45M range in 1.5 is an estimate from headcount, with two soft assumptions (cost per head, product+eng share of revenue). What would settle it: the CEO's own number, or a Delaware/California filing, or a payment-processor volume disclosure. A3 owns this; do not repeat the range as fact.
2. How many clinicians does MEDvidi actually have? The sitemap contains 35 team profiles [SM], but the implied visit volume of a 54-person product organisation cannot be served by 35 part-time contractors. Either the panel is larger than the published profiles, or revenue is at the bottom of the estimated range. What would settle it: the count of distinct prescribers, or a state-board licence search — A5's territory.
3. Traffic order of magnitude. No credible free source for MEDvidi's monthly sessions was reachable; Trustpilot, Similarweb-class data and Reddit's search API all refused unauthenticated requests from this session. The comparison in 1.5 therefore leans on App Store rating counts, which MEDvidi does not participate in at all. What would settle it: a paid traffic tool, or MEDvidi's own analytics in the interview. A2 may have gone further.
4. Whether any competitor targets MEDvidi by name. Klarity publishes "X vs Y" comparison posts (e.g. "Klarity Vs. Circle Medical", May 2026) [REV]; this Area found no "vs MEDvidi" page in the sources it could reach, but the check was not exhaustive — Klarity's sitemap is an index and its post inventory was not enumerated. Being absent from rivals' comparison content is a share-of-voice signal worth confirming.
5. The DOJ primary document for the Done sentencing was not read. justice.gov returned HTTP 403 to this session, so the sentence lengths, the $90M/$100M figure and the 37-million- pill figure rest on trade coverage of the release [PRESS-DONE]. A4 should quote the primary. Nothing in this Area's argument changes if the numbers move; the fact of a custodial sentence for the founder is corroborated across five outlets.
6. Cerebral's live pricing and its current controlled-substance policy. JavaScript-only pages, no usable archive. What would settle it: one manual browser visit.
7. Done's current state coverage is not stated on any page this Area could fetch; the site links to a states page behind its funnel. Left blank in the table rather than guessed.
8. Circle Medical's exact state count and controlled-substance exclusions come from a review site dated May 2026 [REV], not from Circle's own page — its state list renders only in-app. What would settle it: Circle's booking flow, or WELL Health's filings.
9. The MEDVi claims (FDA warning letter February 2026, F BBB rating, OpenLoop data breach) are [REV]-grade and about a different company. What would settle it: the FDA warning-letter database and BBB's own profile. Relevant only as brand-confusion risk.
10. Whether MEDvidi offers superbills or HSA/FSA payment. ADHD Online and Done both advertise out-of-network reimbursement support and HSA/FSA acceptance [COMP-ADHDONLINE] [COMP-DONE]; nothing found on MEDvidi's public pages says either way. If it does not, this is the cheapest unclaimed conversion lever in 1.3.
11. Sesame's per-visit mental-health prices are provider-set; the browse page's embedded price tokens cluster in the $45–$100 band, but that is scraped markup rather than a published price, so only the explicit "$79/month" subscription is quoted.
12. Pettable's ESA pricing could not be read (JavaScript, and the archived capture carries no prices). The ESA price anchor therefore rests on ESA Doctors alone.

5. What this does NOT cover

• The regulatory mechanics themselves. What the DEA telemedicine flexibility is, what a special registration would require, what happens on 2026-12-31, and the enforcement doctrine emerging from the Done prosecution — all A4. This Area only uses the competitive consequences.
• MEDvidi's own funnel, CAC, keyword footprint and paid-media posture. A2 owns the demand engine; competitors' acquisition channels appear here only as one column of the table.
• MEDvidi's unit economics, LTV, retention and revenue shape. A3. The arithmetic in 1.3 and 1.5 is positional, not financial modelling, and is explicitly labelled as estimate where it is one.
• Clinical supply capacity, licensure spread and the operating cost of a visit. A5. The supply-competition material in 1.11 is limited to what rivals offer clinicians.
• Ownership, the Smart IT relationship and the internal org. A7.
• Insurance-based enterprise and payer-facing telemedicine (Teladoc's Integrated Care segment, Amwell, health-system telepsychiatry). Out of scope per SCOPE.md; Teladoc appears here only through the BetterHelp segment, as instrumentation for the cash-pay question.
• Therapy-only competition on clinical grounds. BetterHelp and Talkspace matter in this Area as evidence about who pays, not as competitors for a prescription.
• Non-US operators. Frida is named only to remove it from the set.
• Any assessment of whether stimulant prescribing via telehealth is good medicine. Not this Inquiry's argument, per SCOPE.md.
• Compounded-GLP-1 economics and the compounding-pharmacy legal fight. Adjacent, large, and not MEDvidi's business — MEDvidi writes prescriptions for branded products and does not dispense.

6. What this means for a VP of Product

The first thing to do with this Area is to stop treating MEDvidi's price as a marketing decision. The Wayback record shows a company that ran a membership with automatic refills in 2022, dropped it during the exact window in which Cerebral retreated and Done was investigated, and has held a flat per-visit price for two and a half years since [ARC]. That means the current architecture — one prescription, one billed clinical encounter, no subscription that delivers medication without a visit — is the company's most valuable asset and the reason its closest competitor's founder is in prison while MEDvidi is hiring a VP of Product. It is also completely invisible to patients, to clinicians, and to the market. A VP of Product who arrives and proposes a membership to "improve LTV" will be proposing the business model the DOJ successfully prosecuted. Read the Done indictment before touching packaging. Then build the packaging that gets the retention benefit without decoupling prescription from encounter — prepaid encounter bundles, which MEDvidi has already proven it can price, since the weight-loss page sells a $249 two-visit bundle [WEB].

The second thing is to accept that the wallet is moving and that MEDvidi has already said out loud that it wants to follow it. The company's own FAQ says it is "working on collaborating with insurance providers" [WEB]. Teladoc's Q2 filing is the best available manual for how that project fails: demand for insurance-covered care arrived faster than licensed, credentialed, payer-enrolled provider capacity could serve it, so a company with $774M of cash had to cut marketing 17% and watch segment EBITDA fall 88% [SEC]. The lesson for a $15M–$45M business is brutal and clarifying: the payer transition is a supply-and-workflow program, not a billing integration. If MEDvidi decides to do it, the first hire is credentialing operations and the first product is an eligibility-and-matching engine, not a claims connector. If MEDvidi decides not to do it, that decision needs to be explicit and dated, because every quarter of delay is a quarter in which Circle Medical converts the same click for $35.

The third thing is that the competitive squeeze is specific, not general. Circle Medical takes the identical intent at $120 cash or $0–35 insured, prescribes stimulants in 28 of its 32 states, and has a 30,000-rating mobile app; MEDvidi asks $195 and has no app at all [COMP-CIRCLE] [APPS]. The honest position is that MEDvidi's premium buys three things today: coverage in states Circle has not reached, an appointment inside 24 hours, and a clinician panel selected for willingness to prescribe Schedule II. Only the second is a product property. So the product agenda that follows from this Area is: instrument and defend speed-to-first-appointment as the headline promise, and stop competing on anything that price decides. If the CEO cannot state MEDvidi's median hours-to-first-visit, that is the first metric to stand up.

The fourth thing is the unclaimed moat. The single most consistent failure mode in this entire category is the pharmacy hand-off: MEDvidi's own FAQ documents chains refusing telehealth eRx, controlled substances that cannot be transferred or re-routed, and 72-hour refill approvals [WEB]; Circle Medical reportedly cannot get controlled scripts filled at CVS at all [REV]; Klarity disclaims that its providers may not prescribe controlled substances [COMP-KLARITY]. Nobody has built real-time pharmacy routing — which pharmacy near this patient both stocks this drug and accepts telehealth prescriptions — because it requires operational data nobody has bothered to accumulate. MEDvidi's support organisation is already doing this by hand, which means the data exists in ticket form, which means it is exactly the kind of asset the Agentic AI Receptionist could turn into a product. That is a defensible advantage in the one part of the funnel where patients pay and then fail to get treated.

The fifth thing is to name the cut list, because two lines in the current portfolio do not survive contact with this Area. Weight loss should be cut or re-platformed. The category standardised on $39-then-$149-a-month with medication economics attached; Hims and LifeMD own fulfilment and brand-pharma routes, Found has moved onto insurance, and MEDvidi is selling $195 clinical minutes into that with no drug margin [COMP-HIMS] [COMP-LIFEMD] [COMP-FOUND]. Fighting there costs the scarcest resource MEDvidi has, which is clinician capacity willing to prescribe. ESA letters need an explicit executive decision: they are the only genuinely payer-proof revenue in the business, and they are the line item a regulator would read first [COMP-ESAD]. Neither of these is a PM's call; both are CEO conversations, and a candidate who raises them has demonstrably done the work.

Finally, the tradeoff to name out loud in the room, because it is the real one and it is uncomfortable. MEDvidi's price is sustained by regulatory scarcity, and the same regulatory change that removes its risk also removes its premium. If the DEA framework tightens, MEDvidi's Schedule II franchise shrinks and its cash price loses its justification. If the framework normalises telehealth controlled-substance prescribing with clean rules, then Hims & Hers — 2.9 million subscribers, $753M a quarter, its own pharmacy, and a stated policy of not prescribing amphetamines that is a choice rather than a constraint — can enter MEDvidi's market at a price MEDvidi cannot match [SEC] [COMP-HIMS]. There is no version of the next four quarters in which regulation is simply good news. The strategic answer is therefore not to bet on the rule; it is to convert the current advantage into something a rule change cannot take away: proprietary operational data on prescribing safety and pharmacy fulfilment, a speed guarantee nobody else can honour, and the beginnings of payer plumbing built while cash flow still pays for it. Ask the CEO which of those three he thinks the company is actually building — and whether the second product track is called "AI Clinic" because it is meant to become the moat, or because it is meant to become a separate product to sell.